Mirum Pharmaceuticals, Inc. (MIRM)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 11:09AM EDT. Market open.
| Previous close | 25.60 |
| Open | 26.01 |
| Bid | 18.83 x 200 |
| Ask | 25.99 x 100 |
| Day's range | 25.68 - 26.22 |
| 52-week range | 23.14 - 35.56 |
| Volume | |
| Avg. volume | 495,320 |
| Market cap | 1.22B |
| Beta (5Y monthly) | 1.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
FOSTER CITY, Calif., May 01, 2024--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2024 financial results on May 8, 2024. Mirum will also host a conference call to discuss the first quarter 2024 financial results and recent corporate progress.
- Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., April 11, 2024--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Business Wire
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
FOSTER CITY, Calif., April 02, 2024--Mirum's LIVMARLI Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
© 2024 Yahoo. All rights reserved.